Across TCGA pan-cancer cohorts, FAM186A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM186A data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FAM186A Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM186A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, KIRP, and ACC are the cancer types where FAM186A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.965	0.824	.006	30	view →
KIRP	DFS	Median	II,III,IV	0.037	0.783	<.001	21	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
BRCA	DFS	Median	All	0.879	0.950	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FAM186A tumor-vs-normal RNA expression · all FAM186A data types